Stoke Therapeutics, Inc. (STOK)
NASDAQ: STOK · Real-Time Price · USD
31.27
+1.08 (3.58%)
Oct 13, 2025, 1:16 PM EDT - Market open
Stoke Therapeutics Revenue
Stoke Therapeutics had revenue of $13.82M in the quarter ending June 30, 2025, with 186.01% growth. This brings the company's revenue in the last twelve months to $199.89M, up 1,218.82% year-over-year. In the year 2024, Stoke Therapeutics had annual revenue of $36.56M with 316.34% growth.
Revenue (ttm)
$199.89M
Revenue Growth
+1,218.82%
P/S Ratio
8.67
Revenue / Employee
$1,561,664
Employees
128
Market Cap
1.71B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 36.56M | 27.78M | 316.34% |
Dec 31, 2023 | 8.78M | -3.63M | -29.22% |
Dec 31, 2022 | 12.41M | - | - |
Dec 31, 2021 | - | - | - |
Dec 31, 2020 | - | - | - |
Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 422.82B |
Johnson & Johnson | 90.63B |
Merck & Co. | 63.62B |
AbbVie | 58.33B |
AstraZeneca | 56.50B |
Novartis AG | 55.19B |
Eli Lilly and Company | 53.26B |
Novo Nordisk | 49.11B |
STOK News
- 3 days ago - Stoke Therapeutics and Biogen Present New Data at the 54th Child Neurology Society (CNS) Annual Meeting that Support the Potential of Zorevunersen as a Disease-Modifying Medicine for Dravet Syndrome - Business Wire
- 7 days ago - Stoke Therapeutics Appoints Ian F. Smith as Chief Executive Officer - Business Wire
- 26 days ago - Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) - Business Wire
- 5 weeks ago - Stoke Therapeutics and Biogen Present Data at the 36th International Epilepsy Congress that Support the Potential for Zorevunersen to be the First Disease-Modifying Medicine for Dravet Syndrome - Business Wire
- 6 weeks ago - Stoke Therapeutics to Present at Upcoming Investor Conferences in September 2025 - Business Wire
- 7 weeks ago - Stoke Therapeutics and Biogen Announce Presentations of Clinical Data from Studies of Zorevunersen for the Potential Treatment of Dravet Syndrome at the 36th International Epilepsy Congress - Business Wire
- 2 months ago - Stoke Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Updates - Business Wire
- 2 months ago - Stoke Therapeutics and Biogen Announce First Patient Dosed in Phase 3 EMPEROR Study of Zorevunersen, a Potential Disease-Modifying Treatment for Dravet Syndrome - Business Wire